Literature DB >> 34935399

MRI Screening of BRCA Mutation Carriers: Comparison of Standard Protocol and Abbreviated Protocols With and Without T2-Weighted Images.

Isaac Daimiel Naranjo1,2, Julie Sogani1, Carolina Saccarelli1, Joao V Horvat1, Varadan Sevilimedu3, Mary C Hughes1, Roberto Lo Gullo1, Maxine S Jochelson1, Jeffrey Reiner1, Katja Pinker1,4.   

Abstract

BACKGROUND. Increasing evidence supports the role of abbreviated MRI protocols for breast cancer detection. However, abbreviated protocols have been poorly studied in patients who are BRCA1 or BRCA2 mutation carriers. Furthermore, the need for T2-weighted sequences in abbreviated protocols remains controversial. OBJECTIVE. The purpose of this study was to compare, in the evaluation of patients with BRCA mutations, the diagnostic performance of a standard full breast MRI protocol with the performance of abbreviated protocols that included and did not include a T2-weighted sequence. METHODS. This retrospective study included 292 patients (mean age, 47.9 years) who were BRCA1 or BRCA2 mutation carriers who underwent 427 screening breast MRI examinations according to a standard full protocol who could be classified as having benign (n = 407) or malignant (n = 20) findings based on histopathology or imaging follow-up. Four readers independently assessed examinations in three separate sessions (theoretic abbreviated protocol, which included the first postcontrast acquisition; theoretic abbreviated protocol with addition of a T2-weighted sequence; and the standard full protocol) and assigned BI-RADS categories. Categories 3-5 were considered to represent positive examinations. Interreader agreement was assessed, and diagnostic performance was compared by use of pooled reader data. RESULTS. Interreader agreement on BI-RADS category, expressed as kappa values, was 0.55 for the standard, 0.45 for the abbreviated, and 0.57 for the abbreviated plus T2-weighted protocols. Pooled sensitivity was 94% for the standard, 92% for the abbreviated, and 90% for the abbreviated plus T2-weighted protocols (all p > .001). Pooled specificity was 80% for the standard, 71% for the abbreviated, and 83% for the abbreviated plus T2-weighted protocols (p < .001 for abbreviated plus T2-weighted compared with both standard and abbreviated). Pooled PPV was 19% for the standard, 14% for the abbreviated, and 20% for the abbreviated plus T2-weighted protocols (p < .001 for abbreviated compared with both standard and abbreviated). Pooled NPV was 100% for the standard, 99% for the abbreviated, and 99% for the abbreviated plus T2-weighted (all p > .001) protocols. Pooled accuracy was 80% for the standard, 73% for the abbreviated, and 83% for the abbreviated plus T2-weighted protocols (p < .001 for abbreviated compared with both standard and abbreviated plus T2-weighted). CONCLUSION. The abbreviated protocol without T2-weighted imaging had suboptimal performance. However, addition of the T2-weighted sequence yielded comparable sensitivity and accuracy and a small increase in specificity compared with the full protocol. CLINICAL IMPACT. The findings support implementation of abbreviated MRI with T2-weighted imaging for breast cancer screening of patients with BRCA mutations.

Entities:  

Keywords:  BRCA genes; abbreviated MRI protocol; breast MRI; breast cancer screening; high risk

Mesh:

Year:  2021        PMID: 34935399      PMCID: PMC9422039          DOI: 10.2214/AJR.21.27022

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   6.582


  31 in total

1.  Abbreviated breast dynamic contrast-enhanced MR imaging for lesion detection and characterization: the experience of an Italian oncologic center.

Authors:  Antonella Petrillo; Roberta Fusco; Mario Sansone; Marilena Cerbone; Salvatore Filice; Annamaria Porto; Maria Rosaria Rubulotta; Massimiliano D'Aiuto; Franca Avino; Maurizio Di Bonito; Gerardo Botti
Journal:  Breast Cancer Res Treat       Date:  2017-04-26       Impact factor: 4.872

2.  An Abbreviated Protocol for High-risk Screening Breast Magnetic Resonance Imaging: Impact on Performance Metrics and BI-RADS Assessment.

Authors:  Babita Panigrahi; Lisa Mullen; Eniola Falomo; Benita Panigrahi; Susan Harvey
Journal:  Acad Radiol       Date:  2017-05-11       Impact factor: 3.173

3.  Supplemental MRI Screening for Women with Extremely Dense Breast Tissue.

Authors:  Marije F Bakker; Stéphanie V de Lange; Ruud M Pijnappel; Ritse M Mann; Petra H M Peeters; Evelyn M Monninkhof; Marleen J Emaus; Claudette E Loo; Robertus H C Bisschops; Marc B I Lobbes; Matthijn D F de Jong; Katya M Duvivier; Jeroen Veltman; Nico Karssemeijer; Harry J de Koning; Paul J van Diest; Willem P T M Mali; Maurice A A J van den Bosch; Wouter B Veldhuis; Carla H van Gils
Journal:  N Engl J Med       Date:  2019-11-28       Impact factor: 91.245

4.  Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.

Authors:  Christoph Engel; Christine Fischer; Silke Zachariae; Karolin Bucksch; Kerstin Rhiem; Jutta Giesecke; Natalie Herold; Barbara Wappenschmidt; Verena Hübbel; Monika Maringa; Simone Reichstein-Gnielinski; Eric Hahnen; Claus R Bartram; Nicola Dikow; Sarah Schott; Dorothee Speiser; Denise Horn; Eva M Fallenberg; Marion Kiechle; Anne S Quante; Anne-Sophie Vesper; Tanja Fehm; Christoph Mundhenke; Norbert Arnold; Elena Leinert; Walter Just; Ulrike Siebers-Renelt; Stefanie Weigel; Andrea Gehrig; Achim Wöckel; Brigitte Schlegelberger; Stefanie Pertschy; Karin Kast; Pauline Wimberger; Susanne Briest; Markus Loeffler; Ulrich Bick; Rita K Schmutzler
Journal:  Int J Cancer       Date:  2019-05-22       Impact factor: 7.396

Review 5.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

6.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Authors:  Ellen Warner; Donald B Plewes; Kimberley A Hill; Petrina A Causer; Judit T Zubovits; Roberta A Jong; Margaret R Cutrara; Gerrit DeBoer; Martin J Yaffe; Sandra J Messner; Wendy S Meschino; Cameron A Piron; Steven A Narod
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

7.  Abbreviated breast magnetic resonance protocol: Value of high-resolution temporal dynamic sequence to improve lesion characterization.

Authors:  Guillaume Oldrini; Benjamin Fedida; Julie Poujol; Jacques Felblinger; Isabelle Trop; Philippe Henrot; Emile Darai; Isabelle Thomassin-Naggara
Journal:  Eur J Radiol       Date:  2017-08-01       Impact factor: 3.528

8.  Abbreviated MRI of the Breast: Does It Provide Value?

Authors:  Doris Leithner; Linda Moy; Elizabeth A Morris; Maria A Marino; Thomas H Helbich; Katja Pinker
Journal:  J Magn Reson Imaging       Date:  2018-09-08       Impact factor: 4.813

9.  The potential utility of abbreviated breast MRI (FAST MRI) as a tool for breast cancer screening: a systematic review and meta-analysis.

Authors:  R Geach; L I Jones; S A Harding; A Marshall; S Taylor-Phillips; S McKeown-Keegan; J A Dunn
Journal:  Clin Radiol       Date:  2020-09-30       Impact factor: 2.350

10.  Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening.

Authors:  Christopher E Comstock; Constantine Gatsonis; Gillian M Newstead; Bradley S Snyder; Ilana F Gareen; Jennifer T Bergin; Habib Rahbar; Janice S Sung; Christina Jacobs; Jennifer A Harvey; Mary H Nicholson; Robert C Ward; Jacqueline Holt; Andrew Prather; Kathy D Miller; Mitchell D Schnall; Christiane K Kuhl
Journal:  JAMA       Date:  2020-02-25       Impact factor: 157.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.